Acute Myeloid Leukemia Cell Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2031
All the vital news, analysis, and commentary curated by our industry experts.
Acute Myeloid Leukemia Market Report Overview
The AML market value for the 15 markets (15M) was $3.1 billion in 2021. Acute myeloid (or myelogenous or myelocytic) leukemia (AML) is a malignancy of the hematopoietic system caused by the abnormal proliferation or differentiation of myeloid progenitors in the bone marrow and peripheral blood. AML is relatively rare and has a poor prognosis, particularly in elderly patients. The first approval for cell therapy drugs is anticipated in 2023, which is expected to positively impact the market growth.
The AML market research report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and pipeline therapies with established mechanisms of action and cell therapies by class, including early to late clinical stage pipeline products, with a launch date assessment by market for acute myeloid leukemia (AML). The report also analyzes the clinical and commercial landscapes of AML, with pricing assumptions based on currently marketed products by class of cell therapies, accompanied by a transparent forecast methodology.
|Market Size (2021 in 15M)||$3.1 Billion|
|Key Regions||North America, APAC, Europe, and The Middle East|
|Future Players||Bellicum Pharmaceuticals, Orca Biosystems, University Health Network; Ozmosis Research Inc, Vor BioPharma Inc, MediGene AG, Chongqing Precision Biotech Co Ltd, PersonGen BioTherapautics (Suzhou) Co. Ltd, Anhui Provincial Hospital, Zhejiang University, Shanghai YaKe Biotechnology Co. Ltd, Tianjin First Central Hospital, Guangzhou Bio-gene Technology Co. Ltd|
AML Market Drivers
Anticipated market approval for allogeneic, unclassified “other” cell therapies in 2023 will mark the beginning of a market for cell therapies in AML, which currently has no approved cell therapies. Even though fewer patients are expected to be treated with CAR-T cells compared to other cell therapies, the high anticipated price of CAR-T cells will translate to the highest revenue among cell therapy products.
Furthermore, there is also a very high level of unmet needs in the R/R setting. The frequent use of stem cell transplants that promotes the development of stem cell transplant-augmenting or replacement products, will also drive the market growth.
To know more about the drivers of the AML market, download a free report sample
Acute Myeloid Leukemia Market Unmet Needs
AML presents a few unmet needs that can be well addressed by cell therapies. The most important of these are improved outcomes after transplant, and treatments in the second line and beyond. Many non-classified cell therapies aim to fill the gap in outcomes left by allogeneic stem cell transplants, and GlobalData views this as an important market opportunity.
To know more about the unmet needs in the AML market, download a free report sample
AML Market Segmentation by Regions
The key regions in the AML market are North America, APAC, Europe, and the Middle East. North America had the highest share in 2021.
Acute Myeloid Leukemia Market Analysis by Regions, 2021 (%)
For more regional insights on the Acute Myeloid Leukemia market, download a free report sample
Acute Myeloid Leukemia Market - Competitive Landscape
Some of the future players in the AML market are Bellicum Pharmaceuticals, Orca Biosystems, University Health Network; Ozmosis Research Inc, Vor BioPharma Inc, MediGene AG, Chongqing Precision Biotech Co Ltd, PersonGen BioTherapautics (Suzhou) Co. Ltd, Anhui Provincial Hospital, Zhejiang University, Shanghai YaKe Biotechnology Co. Ltd, Tianjin First Central Hospital, Guangzhou Bio-gene Technology Co. Ltd. Bellicum Pharmaceuticals is the leading sponsor of cell therapy trials in AML, followed by Orca Bio.
For more insights on companies in the AML market, download a free report sample
- This report includes disease epidemiology, a 10-year patient-based forecast for marketed and pipeline therapies with established mechanisms of action, and cell & gene therapies by class, including early- to late clinical-stage pipeline products with launch date assessment by the 8MM market.
- The forecast includes 8 countries for the period of 2021-2031
- Seven markets are extrapolated, obtaining a 15-market value for all AML therapeutics
Reasons to Buy
The report will help to understand:
- What is the target patient pool for cell & gene therapies in each cancer indication?
- Which patient groups are more likely to receive these therapies?
- What does the cell & gene therapy clinical stage pipeline look like in each cancer indication?
- What is the anticipated breakdown between autologous and allogeneic cell therapies?
- When will cell & gene therapies launch in each market?
- What is the total market value projected for the forecast end, in 2031?
Table of Contents
Table of Contents (PowerPoint Deck)
1.2. Report Scope
2. Executive Summary
3. Disease Overview
3.1. Etiology & Epidemiology
3.2. AML Treatment Algorithm
4. Pipeline Drugs Overview
4.1. Pipeline Analysis
4.2. Target Analysis and Clinical Benchmarks
5. Market Outlook
5.1. 10-Year Market Analysis with Drivers and Barriers
6. Unmet Needs
7. Likelihood of Approval Analysis and Phase Transition Success Rate Analysis
8. Competitive Assessment
8.1. Competitive Analysis by Class of Therapy
9. Future Players
9.1. Future Players Based on Pipeline Strength
10.1. Cell Therapies Forecast Methodology Overview
10.2. Pricing of Cell Therapies
10.3. Pipeline Launch Assumptions
10.6. About the Authors
11. Contact Us
Frequently asked questions
What was the AML market size in the 15M in 2021?
The AML market value for the 15 markets (15M) was $3.1 billion in 2021.
What are the key regions in the AML market?
The key regions in the AML market are North America, APAC, Europe, and the Middle East.
Which region has the highest share in the AML market?
North America has the highest share in the acute myeloid leukemia market.
Who are the future players in the AML market?
Some of the future players in the AML market are Bellicum Pharmaceuticals, Orca Biosystems, University Health Network; Ozmosis Research Inc, Vor BioPharma Inc, MediGene AG, Chongqing Precision Biotech Co Ltd, PersonGen BioTherapautics (Suzhou) Co. Ltd, Anhui Provincial Hospital, Zhejiang University, Shanghai YaKe Biotechnology Co. Ltd, Tianjin First Central Hospital, Guangzhou Bio-gene Technology Co. Ltd.
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Business Intelligence & Marketing Manager, SAL Heavy Lift
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
Market Analyst & Management, Liebherr-Werk
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Head of Key Accounts, Saab AB
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Marketing Intelligence Manager, Portugal Foods
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Head of Customer Insight and Research, Standard Chartered
Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.
I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.
I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.
Head of Consumer Sensory Insights, Givaudan
“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.
Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”
Senior Account Manager, TSYS
GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.
I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.
One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.